Bausch + Lomb Presents New Scientific Data And Evaluations Featuring Consumer, Vision Care And Pharmaceutical Products At Optometry's Meeting June 19-22, 2024

5/28/24 9:04:42 AM ET

Ophthalmic Goods

Health Care

Get the next $BLCO alert in real time by email

15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears® Supplement for Dry Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO® (Perfluorohexyloctane Ophthalmic Solution)

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry's Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024.

Get the next $BLCO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLCO

Date	Price Target	Rating	Analyst
10/15/2024	$19.00 → $25.00	In-line → Outperform	Evercore ISI
7/10/2024	$19.00	Outperform	Raymond James
5/6/2024	$16.00 → $18.00	Equal-Weight → Overweight	Morgan Stanley
1/4/2024	$19.00 → $17.00	Outperform → In-line	Evercore ISI
12/12/2023	$16.00	Hold	Stifel
10/3/2023	$20.00	Outperform	Evercore ISI
5/30/2023	$20.00	Equal-Weight	Morgan Stanley
3/9/2023		Hold	Needham

More analyst ratings

$BLCO
Press Releases

Fastest customizable press release news feed in the world

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 94,119,275 units*, or 569,743 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of roughly 690 polar bears1. "Our unique recycling programs continue to be popular with environmentally conscious eye care professionals, patients and consumers," said Amy Butler, vice president, Global Environment, Health, Safety, and Sustainability, Bausch + Lomb. "The collective success of the
11/14/24 7:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care
Bausch + Lomb Announces Third-Quarter 2024 Results
Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP)1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $227 Million Revenue Grew 19% as Reported and 19% on a Constant Currency1 Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments Raising Full-Year 2024 Revenue Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results. "Our focus on execution continues to drive growth, with significant opportunity
10/30/24 7:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. "We're confident that U.S. surgeons will agree with what their Canadian colleagues have already told us: enVista Envy delivers exceptional outcomes and meets cataract patients' high expectations, as well as their own," said Anthony Wallace, vice president and general manager, U.S. Surgical, Bausch + Lomb. A mu
10/14/24 7:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care

$BLCO
Financials

Live finance-specific insights

Bausch + Lomb Announces Third-Quarter 2024 Results
Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP)1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $227 Million Revenue Grew 19% as Reported and 19% on a Constant Currency1 Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments Raising Full-Year 2024 Revenue Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results. "Our focus on execution continues to drive growth, with significant opportunity
10/30/24 7:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, October 30, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49633 Participant Event Dial-in: +1 (888) 506-0062 (North A
10/9/24 8:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care
Bausch + Lomb Announces Second-Quarter 2024 Results
Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP)1 of $209 Million Revenue Grew 17% as Reported and 20% on a Constant Currency1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. "Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitmen
7/31/24 7:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care

$BLCO
Leadership Updates

Live Leadership Updates

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
2/28/24 8:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
2/21/24 7:00:00 AM ET
$BLCO
$EBS
Ophthalmic Goods
Health Care
Biotechnology: Pharmaceutical Preparations
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April
4/12/23 7:00:00 AM ET
$BLCO
Ophthalmic Goods
Health Care

Bausch + Lomb Presents New Scientific Data And Evaluations Featuring Consumer, Vision Care And Pharmaceutical Products At Optometry's Meeting June 19-22, 2024

Chat with this insight

Recent Analyst Ratings for $BLCO

$BLCO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

$BLCO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Bausch + Lomb Corporation

$BLCO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BLCO SEC Filings

Amendment: SEC Form 4 filed by Director Robertson Russel C

Amendment: SEC Form 4 filed by Director Paulson John

Director Robertson Russel C was granted 1,328 shares, increasing direct ownership by 3% to 43,694 units (SEC Form 4)

Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

SEC Form 10-Q filed by Bausch + Lomb Corporation

Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BLCO Press Releases

Fastest customizable press release news feed in the world

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Announces Third-Quarter 2024 Results

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

$BLCO Financials

Live finance-specific insights

Bausch + Lomb Announces Third-Quarter 2024 Results

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30

Bausch + Lomb Announces Second-Quarter 2024 Results

$BLCO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Bausch + Lomb upgraded by Evercore ISI with a new price target

Raymond James initiated coverage on Bausch + Lomb with a new price target

Bausch + Lomb upgraded by Morgan Stanley with a new price target

$BLCO Leadership Updates

Live Leadership Updates

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

$BLCO Market Insights

Live Market Insights

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Raymond James Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $19

Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $15.5

Recent Analyst Ratings for
$BLCO

$BLCO
Insider Purchases

$BLCO
Large Ownership Changes

$BLCO
Insider Trading

$BLCO
SEC Filings

$BLCO
Press Releases

$BLCO
Financials

$BLCO
Analyst Ratings

$BLCO
Leadership Updates

$BLCO
Market Insights